Participants 45 123 6
patients with chronic hepatitis C treated with interferon-alpha and ribavirin:
Participants 300 408 7
patients with chronic hepatitis C during and after treatment with interferon-alpha (IFN-alpha) and ribavirin
Participants 410 418 3
PATIENTS
Participants 503 696 8
previously untreated patients with chronic hepatitis C were treated with IFN-alpha plus ribavirin [17] and randomized for treatment with amantadine (200 mg/day, orally, n=136) or placebo (n=131
Participants 953 1001 5
patients in the control and the amantadine group
Participants 1012 1059 4
the control group but not the amantadine group,
